TRIM72 and myeloid sarcoma: Table 1 presents and compares the main clinical and demographic features of the MS group and the control subjects. The MG53 kit’s limit of detection was determined to be 8.57 pg/mL. The serum MG53 levels of 17 patients in the MS group and 24 subjects in the control group were lower than the detection limit. Upon analysis that excluded those below the detection limit, no difference was observed in the MG53 levels between the MS and control groups (p = 0.969) (Table 2).